Arelili (Adebrelimab) – ES-SCLC | HongKong DengYue Medicine

Arelili Application Scope

Arelili is a humanized IgG4κ monoclonal antibody targeting PD‑L1, used in cancer therapy.

Characteristics

• Ingredients: Adebrelimab (also known as SHR‑1316, HTI‑1088)

• Properties:

  • Humanized IgG4κ anti‑PD‑L1 monoclonal antibody

  • Binds PD‑L1 to block the immune checkpoint and enhance T‑cell response

• Packaging Specification: Supplied as sterile vials containing solution for infusion

• Storage: Store refrigerated at 2–8 °C; protect from light

• Expiry Date: As printed on carton/vial; typically 24 months from manufacture

• Executive Standard: Manufactured per China NMPA Good Manufacturing Practices (GMP)

• Approval Number: Approved by China NMPA in 2023 under “Drug Registration Certificate

• Date of Revision: Most recent label update aligns with 2023 approval

• Manufacturer: Jiangsu Hengrui Medicine Co., Ltd. (marketed as Arelili®/Ariely®)

Guidelines for the Use of Arelili

• Dosage and Administration:

  • Administer via intravenous infusion

  • Dosing schedule and infusion rate per approved label (e.g., every 2–3 weeks)

• Adverse Reactions:

  • Common:

    • immune‑related effects (pneumonitis, hepatitis, colitis)

    • infusion reactions; fatigue

    • rash (based on the PD‑L1 inhibitors class)

• Contraindications: Known severe hypersensitivity to adebrelimab or vial components

• Precautions:

  • Monitor for immune‑mediated toxicity (lungs, liver, endocrine organs)

  • Use caution in patients with autoimmune disease or organ transplant history

Arelili Interactions

• Drug Interactions:

  • No specific interactions reported

  • But immune checkpoint inhibitors may interact with other immunosuppressants

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.